A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
Completed · Phase 1 · NCT07232732
Conditions: Healthy, Obesity, Overweight
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 3
- Sites paid
- 2
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3549492 (drug)
- Dates
- Started 2025-10-27; completion 2026-07-17
- Results posted
- Not yet
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.5M in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sharrell Cooper, M.D Family Medicine · Palm Coast, FL
- Kimberly Cruz, M.D. Pediatrics · Pompano Beach, FL
- Archie V. Bowie II, MD Student in an Organized Health Care Education/Training Program · Odessa, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $1.0M
- Covance Clinical Research LP Dallas $504,254
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.